Medical Management in Focal versus Generalized Epilepsy

Abstract

About 70% of children with new-onset epilepsy have the potential to become seizure-free on antiepileptic drug (AED) monotherapy with appropriately selected first-line medication. In ideal world, physician is expected to achieve best possible seizure control without impacting the quality of life. There is rapid increase in number of AEDs available over last couple of decades. Although not necessarily all of them are superior to old generation drugs in terms of seizure control, certainly there is change in landscape from perspective of tolerability and side-effect profile. Physicians must therefore be familiar with safety, tolerability, therapeutic effects, synergistic combinations as well as AEDs to avoid in specific circumstances. The article attempts to give general overview of available AEDs under broad umbrella of effectiveness against focal and generalized seizures as well as drugs with “broad spectrum.” The emergence of newer AEDs with broad spectrum and favorable side-effect profile is welcome. However, the future lies in better understanding of underlying diverse pathophysiology of clinical symptom “epilepsy” and developing new compounds acting on molecular targets as well as individualizing therapy. Technological advances in molecular genetics research are bringing precision medicine to the fore.

Keywords

epilepsy - generalized seizures - focal seizures - antiepileptic drug

Publication History

Received: 16 November 2020

Accepted: 01 December 2020

Article published online:
02 February 2021

• References

• 1 Rosati A, De Masi S, Guerrini R. Antiepileptic drug treatment in children with epilepsy. CNS Drugs 2015; 29 (10) 847-863
• 2 Nolan SJ, Tudur Smith C, Weston J, Marson AG. Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review. Cochrane Database Syst Rev 2016; 11 (11) CD001031
• 3 Guerrini R, Zaccara G, la Marca G, Rosati A. Safety and tolerability of antiepileptic drug treatment in children with epilepsy. Drug Saf 2012; 35 (07) 519-533
• 4 Lee SK. Old versus new: why do we need new antiepileptic drugs?. J Epilepsy Res 2014; 4 (02) 39-44
• 5 Moavero R, Pisani LR, Pisani F, Curatolo P. Safety and tolerability profile of new antiepileptic drug treatment in children with epilepsy. Expert Opin Drug Saf 2018; 17 (10) 1015-1028
• 6 Moosa ANV. Antiepileptic drug treatment of epilepsy in children. Continuum (Minneap Minn) 2019; 25 (02) 381-407
• 7 Campos MS, Ayres LR, Morelo MR, Marques FA, Pereira LR. Efficacy and tolerability of antiepileptic drugs in patients with focal epilepsy: systematic review and network meta-analyses. Pharmacotherapy 2016; 36 (12) 1255-1271
• 8 Striano P, Belcastro V, Coppola A, Minetti C, Striano S. Antiepileptic drugs under investigation for treatment of focal epilepsy. Clin Neuropharmacol 2016; 39 (06) 281-287
• 9 Arya R, Giridharan N, Anand V, Garg SK. Clobazam monotherapy for focal or generalized seizures. Cochrane Database Syst Rev 2018; 7 (07) CD009258
• 10 Balagura G, Iapadre G, Verrotti A, Striano P. Moving beyond sodium valproate: choosing the right anti-epileptic drug in children. Expert Opin Pharmacother 2019; 20 (12) 1449-1456
• 11 Faught E, Helmers S, Thurman D, Kim H, Kalilani L. Patient characteristics and treatment patterns in patients with newly diagnosed epilepsy: a US database analysis. Epilepsy Behav 2018; 85: 37-44
• 12 Brorson LO, Eriksson M, Blomberg K, Stenninger E. Fifty years' follow-up of childhood epilepsy: medical outcome, morbidity, and medication. Epilepsia 2019; 60 (03) 381-392
• 13 Asadi-Pooya AA, Beniczky S, Rubboli G, Sperling MR, Rampp S, Perucca E. A pragmatic algorithm to select appropriate antiseizure medications in patients with epilepsy. Epilepsia 2020; 61 (08) 1668-1677
• 14 Valeta T, Panayiotopoulos CP. Treatment of classic syndromes in idiopathic focal epilepsies in childhood. J Pediatr Epilepsy 2016; 5 (03) 142-146
• 15 Ahadi P, Nasiri J, Ghazavi MR, Mosavian T, Mansouri V. A comparative study on the efficacy of levetiracetam and carbamazepine in the treatment of rolandic seizures in children: an open-label randomized controlled trial. J Res Pharm Pract 2020; 9 (02) 68-72
• 16 Akhondian J, Ashrafzadeh F, Eslamiyeh H. Levetiracetam (Levebel) versus carbamazepine monotherapy for focal epilepsy in children: a randomized clinical trial. Iran J Child Neurol 2020; 14 (02) 69-77
• 17 Chung S, Ceja H, Gawłowicz J, McShea C, Schiemann J, Lu S. Levetiracetam extended release for the treatment of patients with partial-onset seizures: a long-term, open-label follow-up study. Epilepsy Res 2016; 120: 7-12
• 18 Janković SM. Evaluation of zonisamide for the treatment of focal epilepsy: a review of pharmacokinetics, clinical efficacy and adverse effects. Expert Opin Drug Metab Toxicol 2020; 16 (03) 169-177
• 19 Shih JJ, Whitlock JB, Chimato N, Vargas E, Karceski SC, Frank RD. Epilepsy treatment in adults and adolescents: expert opinion, 2016. Epilepsy Behav 2017; 69: 186-222
• 20 Coppola G, Iapadre G, Operto FF, Verrotti A. New developments in the management of partial-onset epilepsy: role of brivaracetam. Drug Des Devel Ther 2017; 11: 643-657
• 21 Lattanzi S, Zaccara G, Giovannelli F. et al. Antiepileptic monotherapy in newly diagnosed focal epilepsy. A network meta-analysis. Acta Neurol Scand 2019; 139 (01) 33-41
• 22 Bresnahan R, Hounsome J, Jette N, Hutton JL, Marson AG. Topiramate add-on therapy for drug-resistant focal epilepsy. Cochrane Database Syst Rev 2019; 10 (10) CD001417
• 23 Panebianco M, Bresnahan R, Ramaratnam S, Marson AG. Lamotrigine add-on therapy for drug-resistant focal epilepsy. Cochrane Database Syst Rev 2020; 3 (03) CD001909
• 24 Castillo SM, Schmidt DB, White S, Shukralla A. WITHDRAWN: oxcarbazepine add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev 2016; 11 (11) CD002028
• 25 Garoufi A, Vartzelis G, Tsentidis C. et al. Weight gain in children on oxcarbazepine monotherapy. Epilepsy Res 2016; 122: 110-113
• 26 Coppola G, Piccorossi A, Operto FF, Verrotti A. Anticonvulsant drugs for generalized tonic-clonic epilepsy. Expert Opin Pharmacother 2017; 18 (09) 925-936
• 27 İşgüder R, Güzel O, Ceylan G, Yılmaz Ü, Ağın H. A comparison of intravenous levetiracetam and valproate for the treatment of refractory status epilepticus in children. J Child Neurol 2016; 31 (09) 1120-1126
• 28 Abbaskhanian A, Shahmohammadi S. Add-on levetiracetam in children with refractory epilepsy: a systematic review. J Pediatr Rev 2016;4(02)
• 29 Miskin C, Khurana DS, Valencia I, Legido A, Hasbani DM, Carvalho KS. Efficacy and tolerability of lacosamide in the treatment of children with refractory generalized epilepsy. J Child Neurol 2016; 31 (07) 925-928
• 30 Rüegger AD, Freeman JL, Harvey AS. Lacosamide in children with drug-resistant epilepsy. J Pediatr Child Health 2019; 55 (02) 194-198
• 31 Aungaroon G, Holland KD, Horn PS, Standridge SM, Imming CM. Drug-resistant epilepsy in children with partial onset epilepsy treated with carbamazepine. Int J Neurosci 2017; 127 (10) 849-853
• 32 Nissenkorn A, Tzadok M, Bar-Yosef O, Ben-Zeev B. Treatment with brivaracetam in children: the experience of a pediatric epilepsy center. Epilepsy Behav 2019; 101 (Pt A): 106541
• 33 Brigo F, Bragazzi NL, Nardone R, Trinka E. Efficacy and tolerability of brivaracetam compared to lacosamide, eslicarbazepine acetate, and perampanel as adjunctive treatments in uncontrolled focal epilepsy: results of an indirect comparison meta-analysis of RCTs. Seizure 2016; 42: 29-37
• 34 Patel AD, Badalamenti V, Gasalla T, Elmoufti S, Elshoff JP. Safety and tolerability of adjunctive brivaracetam in children with focal seizures: Interim analysis of pooled data from two open-label trials. Eur J Paediatr Neurol 2020; 25: 68-76
• 35 Pack AM. Perampanel: Another choice for patients with idiopathic generalized epilepsy who have tonic-clonic seizures. Epilepsy Curr 2016; 16 (01) 27-28
• 36 Rohracher A, Brigo F, Höfler J. et al. Perampanel for the treatment of primary generalized tonic-clonic seizures in idiopathic generalized epilepsy. Expert Opin Pharmacother 2016; 17 (10) 1403-1411
• 37 Operto FF, Pastorino GMG, Mazza R. et al. Perampanel tolerability in children and adolescents with focal epilepsy: effects on behavior and executive functions. Epilepsy Behav 2020; 103 (Pt A): 106879
• 38 Caraballo RH, Pociecha J, Reyes G. et al. Rufinamide as add-on therapy in children with epileptic encephalopathies other than Lennox-Gastaut syndrome: a study of 34 patients. Epilepsy Behav 2020; 108: 107074
• 39 Panayiotopoulos CP. The Epilepsies: Seizures, Syndromes and Management. Oxfordshire, UK: 2005
• 40 Hahn J, Lee H, Kang HC. et al. Clobazam as an adjunctive treatment for infantile spasms. Epilepsy Behav 2019; 95: 161-165
• 41 Yi Z, Wu H, Yu X. et al. High-dose prednisone therapy for infantile spasms and late-onset epileptic spasms in China: the addition of topiramate provides no benefit. Seizure 2019; 71: 174-178
• 42 Chugani HT, Ilyas M, Kumar A. et al. Surgical treatment for refractory epileptic spasms: the Detroit series. Epilepsia 2015; 56 (12) 1941-1949
• 43 Anderson LL, Absalom NL, Abelev SV. et al. Coadministered cannabidiol and clobazam: preclinical evidence for both pharmacodynamic and pharmacokinetic interactions. Epilepsia 2019; 60 (11) 2224-2234
• 44 Lagae L, Sullivan J, Knupp K. et al; FAiRE DS Study Group. Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial. Lancet 2019; 394 (10216): 2243-2254
• 45 Polster T. Individualized treatment approaches: Fenfluramine, a novel antiepileptic medication for the treatment of seizures in Dravet syndrome. Epilepsy Behav 2019; 91: 99-102
• 46 Buck ML, Goodkin HP. Stiripentol: a novel antiseizure medication for the management of dravet syndrome. Ann Pharmacother 2019; 53 (11) 1136-1144
• 47 Brigo F, Igwe SC, Bragazzi NL. Stiripentol add-on therapy for focal refractory epilepsy. Cochrane Database Syst Rev 2018; 5 (05) CD009887
• 48 Brigo F, Striano P, Balagura G, Belcastro V. Emerging drugs for the treatment of Dravet syndrome. Expert Opin Emerg Drugs 2018; 23 (04) 261-269
• 49 Arzimanoglou A, Ferreira JA, Satlin A. et al. Safety and pharmacokinetic profile of rufinamide in pediatric patients aged less than 4 years with Lennox-Gastaut syndrome: an interim analysis from a multicenter, randomized, active-controlled, open-label study. Eur J Paediatr Neurol 2016; 20 (03) 393-402
• 50 Jaraba S, Santamarina E, Miró J. et al. Rufinamide in children and adults in routine clinical practice. Acta Neurol Scand 2017; 135 (01) 122-128
• 51 Devinsky O, Marsh E, Friedman D. et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol 2016; 15 (03) 270-278
• 52 Brigo F, Igwe SC. Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. Cochrane Database Syst Rev 2017; 2 (02) CD003032
• 53 Brigo F, Igwe SC, Lattanzi S. Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. Cochrane Database Syst Rev 2019; 2 (02) CD003032
• 54 Cao J, Lin XX, Ma XM, Liu H. The efficacy and safety of lamotrigine for absence seizures in children and adolescents: a systematic review and meta-analysis. J Clin Neurosci 2020; 71: 199-204
• 55 IJff DM, van Veenendaal TM, Debeij-van Hall MH. et al. The cognitive profile of ethosuximide in children. Paediatr Drugs 2016; 18 (05) 379-385
• 56 Mariani E, Rossi LN, Vajani S. Interictal paroxysmal EEG abnormalities in childhood absence epilepsy. Seizure 2011; 20 (04) 299-304
• 57 Grosso S, Balestri M, Di Bartolo RM. et al. Oxcarbazepine and atypical evolution of benign idiopathic focal epilepsy of childhood. Eur J Neurol 2006; 13 (10) 1142-1145
• 58 Wirrell E. Infantile, childhood, and adolescent epilepsies. Continuum (Minneap Minn) 2016; 22 (1 Epilepsy): 60-93
• 59 French JA, Lawson JA, Yapici Z. et al. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet 2016; 388 (10056): 2153-2163
• 60 Samueli S, Dressler A, Gröppel G, Scholl T, Feucht M. Everolimus in infants with tuberous sclerosis complex-related West syndrome: first results from a single-center prospective observational study. Epilepsia 2018; 59 (09) e142-e146
• 61 Sazgar M, Bourgeois BF. Aggravation of epilepsy by antiepileptic drugs. Pediatr Neurol 2005; 33 (04) 227-234
• 62 Epi PMC. EpiPM Consortium. A roadmap for precision medicine in the epilepsies. Lancet Neurol 2015; 14 (12) 1219-1228
• 63 Milligan CJ, Li M, Gazina EV. et al. KCNT1 gain of function in 2 epilepsy phenotypes is reversed by quinidine. Ann Neurol 2014; 75 (04) 581-590
• 64 Orhan G, Bock M, Schepers D. et al. Dominant-negative effects of KCNQ2 mutations are associated with epileptic encephalopathy. Ann Neurol 2014; 75 (03) 382-394
• 65 Pierson TM, Yuan H, Marsh ED. et al; PhD for the NISC Comparative Sequencing Program. GRIN2A mutation and early-onset epileptic encephalopathy: personalized therapy with memantine. Ann Clin Transl Neurol 2014; 1 (03) 190-198
• 66 Krueger DA, Wilfong AA, Holland-Bouley K. et al. Everolimus treatment of refractory epilepsy in tuberous sclerosis complex. Ann Neurol 2013; 74 (05) 679-687
• 67 Perucca E. Antiepileptic drugs: evolution of our knowledge and changes in drug trials. Epileptic Disord 2019; 21 (04) 319-329
• 68 Wiemer-Kruel A, Haberlandt E, Hartmann H, Wohlrab G, Bast T. Modified Atkins diet is an effective treatment for children with Doose syndrome. Epilepsia 2017; 58 (04) 657-662
• 69 Mehdizadeh A, Barzegar M, Negargar S, Yahyavi A, Raeisi S. The current and emerging therapeutic approaches in drug-resistant epilepsy management. Acta Neurol Belg 2019; 119 (02) 155-162